Skip to main content

Table 1 Characteristics of patients with severe sepsis with or without progression of AKI

From: Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study

 

Data available

Progression of AKI

Data available

No progression of AKI

P-value

N = 153

N = 270

Age, years

153

64.0 (51.0 to 78.0)

270

63.0 (52.0 to 73.0)

0.1

Gender, male

153

92 (60.1)

270

184 (68.1)

0.1

Baseline creatinine available

153

108 (70.6)

270

184 (68.1)

0.6

Comorbidity

 

  Hypertension

153

81 (52.9)

270

126 (46.7)

0.22

  Systolic heart failure or arteriosclerosis

153

30 (19.6)

270

45 (16.7)

0.45

  COPD

153

15 (9.8)

270

38 (14.1)

0.2

  Chronic kidney disease

153

17 (11.1)

270

7 (2.6)

<0.001

  Chronic liver disease

153

8 (5.2)

270

12 (4.4)

0.72

  Diabetes mellitus

153

42 (27.5)

270

50 (18.5)

0.032

Hypotension prior to ICU

151

64 (42.4)

267

75 (28.1)

0.003

Hypovolemia prior to ICU

151

78 (51.7)

268

96 (35.8)

0.002

Radiocontrast dye prior to ICU

153

44 (28.8)

268

52 (19.4)

0.03

Emergency admission

153

148 (96.7)

270

267 (98.9)

0.12

Operative admission

153

49 (32.0)

270

59 (21.9)

0.02

Community acquired infection

152

76 (50.0)

270

137 (50.7)

0.88

Source of infection

  Pulmonary

139

70 (50.4)

246

155 (63.0)

0.02

  Abdominal

139

45 (32.4)

246

52 (21.1)

0.02

  Genitourinary

139

14 (10.1)

246

12 (4.9)

0.05

  Soft tissue

139

14 (10.1)

246

28 (12.4)

0.7

SAPS II points

153

43.0 (35.0 to 55.0)

270

38.0 (30.0 to 46.0)

<0.001

SAPS II points without age and renal components

153

24.0 (18.0 to 30.0)

270

24.0 (17.0 to 31.0)

0.7

SOFA D1 points

153

9.0 (7.0 to 11.0)

270

7.0 (5.0 to 9.0)

<0.001

SOFA D1 points, without renal points

153

8.0 (6.0 to 10.0)

270

7.0 (5.0 to 9.0)

0.001

During ICU stay

  Mechanical ventilation

153

117 (76.5)

270

168 (62.2)

0.003

  Use of sepsis corticosteroids

151

55 (36.4)

264

46 (17.4)

<0.001

  Any vasoactive treatment

153

134 (87.6)

270

181 (67.0)

<0.001

  Furosemide

153

131 (85.6)

270

189 (70.0)

<0.001

  Dose of furosemide (iv) per ICU day, mg/day

153

13.6 (3.5-33.9)

270

4.2 (0.0-16.0)

<0.001

  Aminoglycoside antibiotics

153

1 (0.7)

270

6 (2.2)

0.22

  Peptidoglycan antibiotics

153

16 (10.5)

270

29 (10.7)

0.93

  ACE inhibitor or ARB

153

10 (6.5)

270

26 (9.6)

0.27

  NSAID

153

5 (3.3)

270

17 (6.3)

0.18

  Radiocontrast dye

153

15 (9.8)

270

33 (12.2)

0.45

Length of stay

     

  ICU

153

5.7 (3.3 to 10.3)

270

3.8 (2.0 to 7.0)

<0.001

  Hospital

153

16.0 (9.5 to 26.5)

270

15.0 (9.0 to 23.8)

034

90-day mortality

153

50 (32.7)

270

51 (18.9)

0.001

  1. Values are expressed as median (IQR) or count (percentage). Progression of acute kidney injury (AKI) is defined as onset of new AKI or worsening of AKI by at least one Kidney Disease: Improving Global Outcomes (KDIGO) stage within the first 5 days after ICU admission. COPD, chronic obstructive pulmonary disease; chronic kidney disease (CKD) was defined as structural or functional abnormalities of the kidney or glomerular filtration rate (GFR) <60 ml/minute/1.73 m2 at least one week prior to ICU admission; hypotension, systolic blood pressure <90 mmHg for 1 h; hypovolemia, by judgement of clinicians; SAPS II, simplified acute physiology score, SOFA D1, sequential organ failure assessment, first score during the ICU stay; iv, intravenous; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; NSAID, non-steroidal anti-inflammatory drug.
Back to article page

Critical Care

ISSN: 1364-8535